- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
March 26, 2024Ronald Schutz, Brendan Johnson Named to Forbes Top 200 Lawyers in the United States
-
March 21, 2024Robins Kaplan Firm Members Appointed to Law360 Editorial Boards
-
March 20, 2024Brandon Vaughn Inducted into The International Society of Barristers
-
April 5, 2024Mass Torts Made Perfect
-
April 17, 2024American Antitrust Institute Virtual CLE Lunch & Learn
-
May 2-3, 2024ACI Advanced Forum on Managed Care Disputes and Litigation
-
March 14, 2024How Many Cases Have You Tried to a Verdict?
-
March 2024Do We Have to Share That Information? Attorney-Client Privilege in the Multi-Entity Context
-
March 2024Sellers of a Business: Know Thyself.
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
New ANDA Cases
Spring 2016
Case Name | Date Filed | Judge | Drug | Patent No(s). |
---|---|---|---|---|
Valeant Pharms. Int’l Inc. v. Mylan Pharms., Inc., 16-0035 (D.N.J.) | Jan. 4, 2016 | Hon. Stanley R. Chesler | Relistor® (methylnaltrexone bromide injection) |
8,247,425
8,420,663
8,552,025
8,822,490
|
Otsuka Pharm. Co., Ltd. v. Indoco Remedies Ltd., 16-0086 (D.N.J.) | Jan. 7, 2016 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) | 9,089,567 |
Jazz Pharms., Inc. v. Wockhardt Bio AG, 16-0099 (D.N.J.) | Jan. 7, 2016 | Hon. Esther Salas | Xyrem® (sodium oxybate oral solution) | 9,050,302 |
Alcon Pharms. Ltd. v. Watson Labs., Inc., 16-0101 (D.N.J.) | Jan. 7, 2016 | Hon. Peter G. Sheridan | Ciprodex® (ciprofloxacin / dexamethasone otic suspension) |
6,284,804
6,359,016
|
Helsinn Healthcare S.A. v. Sagent Pharms., Inc., 16-0173 (D.N.J.) | Jan. 11, 2016 | Hon. Mary L. Cooper | Aloxi® (palonosetron hydrochloride for injection) |
7,947,724
7,947,725
7,960,424
8,598,219
8,729,094
|
Prostrakan, Inc. v. Actavis Labs. UT, Inc., 16-0044 (E.D. Tex.) | Jan. 13, 2016 | Hon. Robert W. Schroeder, III | Sancuso® (granisetron extended-release transdermal film) | 7,608,282 |
Prostrakan, Inc. v. Actavis Labs. UT, Inc., 16-0015 (D. Del.) | Jan. 15, 2016 | Hon. Leonard P. Stark | Sancuso® (granisetron extended-release transdermal film) | 7,608,282 |
Hospira, Inc. v. Fresenius Kabi USA, LLC, 16-0651 (N.D. Ill.) | Jan. 15, 2016 | Hon. Rebecca R. Pallmeyer | Precedex® (dexmedetomidine hydrochloride injection) |
8,242,158
8,338,470
8,455,527
8,648,106
|
Rosellini Scientific, LLC v. Grunenthal Gmbh, IPR2016-00471 (PTAB) | Jan. 15, 2016 | N/A |
Nucynta® (tapentadol hydrochloride tablets)
Nucynta® ER (tapentadol hydrochloride extended-release tablets)
Nucynta® (tapentadol hydrochloride solution)
|
7,994,364 |
Purdue Pharma L.P. v. Abhai, LLC, 16-0025 (D. Del.) | Jan. 19, 2016 | Hon. Sue L. Robinson | OxyContin® (oxycodone hydrochloride extended-release tablets) |
7,674,799
7,674,800
7,683,072
8,114,383
8,309,060
8,337,888
8,808,741
8,894,987
8,894,988
9,060,976
9,073,933
|
Purdue Pharma L.P. v. Alvogen Pine Brook, LLC, 16-0026 (D. Del.) | Jan. 20, 2016 | Hon. Gregory M. Sleet | Hysingla® ER (hydrocodone bitartrate extended-release tablets) |
9,198,863
9,205,056
|
Cubist Pharms. LLC v. Dr. Reddy’s Labs., Ltd., 16-0030 (D. Del.) | Jan. 21, 2016 | Hon. Gregory M. Sleet | Cubicin® (daptomycin for injection) |
6,468,967
6,852,689
8,058,238
8,129,342
|
Purdue Pharma L.P. v. Abhai, LLC, 16-0058 (M.D. Fla.) | Jan. 21, 2016 | Hon. Timothy J. Corrigan | OxyContin® (oxycodone hydrochloride extended-release tablets) |
7,674,799
7,674,800
7,683,072
8,114,383
8,309,060
8,337,888
8,808,741
8,894,987
8,894,988
9,060,976
9,073,933
|
Cubist Pharms. LLC v. Dr. Reddy’s Labs., Ltd., 16-0372 (D.N.J.) | Jan. 21, 2016 | Hon. Freda L. Wolfson | Cubicin® (daptomycin for injection) |
6,468,967
6,852,689
8,058,238
8,129,342
|
Millennium Pharms., Inc. v. Wockhardt Bio AG, 16-0034 (D. Del.) | Jan. 22, 2016 | Hon. Gregory M. Sleet | Velcade® (bortezomib for injection) |
6,713,446
6,958,319
|
Otsuka Pharm. Co., Ltd. v. Orchid Pharma Ltd., 16-0405 (D.N.J.) | Jan. 22, 2016 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) |
8,017,615
8,580,796
8,642,760
8,518,421
|
Otsuka Pharm. Co., Ltd. v. Orchid Pharma Ltd., 16-0424 (D.N.J.) | Jan. 25, 2015 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) | 9,089,567 |
Horizon Pharma, Inc. v. Actavis Labs. FL, Inc., 16-0426 (D.N.J.) | Jan. 25, 2016 | Hon. Mary L. Cooper | Vimovo® (naproxen / esomeprazole magnesium delayed-release tablets) |
9,161,920
9,198,888
|
Novartis Pharms. Corp. v. Wockhardt Bio AG, 16-0040 (D. Del.) | Jan. 26, 2016 | Hon. Leonard P. Stark | Gleevec® (imatinib mesylate tablets) |
6,894,051
RE43,932
|
Jazz Pharms., Inc. v. Roxane Labs., Inc., 16-0469 (D.N.J.) | Jan. 27, 2016 | Hon. Esther Salas | Xyrem® (sodium oxybate oral solution) | 9,050,302 |
Mylan Pharms. Inc. v. UCB Pharma Gmbh, IPR2016-00510 (PTAB) | Jan. 28, 2016 | N/A | Toviaz® (fesoterodine fumarate extended-release tablets) | 6,858,650 |
Mylan Pharms. Inc. v. UCB Pharma Gmbh, IPR2016-00512 (PTAB) | Jan. 28, 2016 | N/A | Toviaz® (fesoterodine fumarate extended-release tablets) | 7,384,980 |
Mylan Pharms. Inc. v. UCB Pharma Gmbh, IPR2016-00514 (PTAB) | Jan. 28, 2016 | N/A | Toviaz® (fesoterodine fumarate extended-release tablets) | 7,855,230 |
Mylan Pharms. Inc. v. UCB Pharma Gmbh, IPR2016-00516 (PTAB) | Jan. 28, 2016 | N/A | Toviaz® (fesoterodine fumarate extended-release tablets) | 8,338,478 |
Mylan Pharms. Inc. v. UCB Pharma Gmbh, IPR2016-00517 (PTAB) | Jan. 28, 2016 | N/A | Toviaz® (fesoterodine fumarate extended-release tablets) | 7,985,772 |
Otsuka Pharm. Co., Ltd. v. Stason Industrial Corp., 16-0555 (D.N.J.) | Feb. 1, 2016 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) | 9,089,567 |
Otsuka Pharm. Co., Ltd. v. Stason Industrial Corp., 16-0557 (D.N.J.) | Feb. 1, 2016 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) | 9,125,939 |
Orexo AB v. Actavis Elizabeth LLC, 16-0062 (D. Del.) | Feb. 2, 2016 | Hon. Sue L. Robinson | Zubsolv® (buprenorphine hydrochloride / naloxone hydrochloride dihydrate sublingual tablets) |
8,454,996
8,940,330
|
The Medicines Co. v. Eagles Pharms., Inc., 16-569 (D.N.J.) | Feb. 2, 2016 | Hon. Stanley R. Chesler | Angiomax® (bivalirudin for injection) |
7,713,928
7,803,762
|
Argentum Pharms. LLC v. Alcon Research, Ltd., IPR2016-00544 (PTAB) | Feb. 2, 2016 | N/A | Pazio® (olopatadine hydrochloride ophthalmic solution) | 8,791,154 |
Amneal Pharms. LLC v. Jazz Pharms., Inc., IPR2016-00546 (PTAB) | Feb. 2, 2016 | N/A | Xyrem® (sodium oxybate oral solution) | 8,772,306 |
Lupin Ltd. v. Vertex Pharms., Inc., IPR2016-00558 (PTAB) | Feb. 3, 2016 | N/A | Lexiva® (fosamprenavir calcium) | 6,436,989 |
Bayer Intellectual Property Gmbh v. Invagen Pharms., Inc., 16-0064 (D. Del.) | Feb. 4, 2016 | Hon. Sue L. Robinson | Xarelto® (rivaroxaban tablets) |
7,157,456
7,585,860
7,592,339
|
Eli Lilly and Co. v. Dr. Reddy’s Labs., Ltd., 16-0308 (S.D. Ind.) | Feb. 5, 2016 | Hon. Jane Magnus-Stinson | Alimta® (pemetrexed disodium injection) | 7,772,209 |
Horizon Pharma Ireland Ltd. v. Actavis Labs. UT, Inc., 16-0645 (D.N.J.) | Feb. 5, 2016 | Hon. Noel L. Hillman | Pennsaid® (diclofenac sodium topical solution) | 9,220,784 |
Horizon Pharma Ireland Ltd. v. Amneal Pharms. LLC, 16-0646 (D.N.J.) | Feb. 5, 2016 | Hon. Noel L. Hillman | Pennsaid® (diclofenac sodium topical solution) | 9,220,784 |
Horizon Pharma Ireland Ltd. v. Teligent, Inc., 16-0647 (D.N.J.) | Feb. 5, 2016 | Hon. Noel L. Hillman | Pennsaid® (diclofenac sodium topical solution) | 9,220,784 |
Horizon Pharma Ireland Ltd. v. Lupin Ltd., 16-0732 (D.N.J.) | Feb. 5, 2016 | Hon. Noel L. Hillman | Pennsaid® (diclofenac sodium topical solution) | 9,220,784 |
Dr. Reddy’s Labs., Ltd. v. Helsinn Healthcare S.A., PGR2016-00007 (PTAB) | Feb. 5, 2016 | N/A | Aloxi® (palonosetron hydrochloride for injection) | 9,173,942 |
Dr. Reddy’s Labs., Ltd. v. Helsinn Healthcare S.A., PGR2016-00008 (PTAB) | Feb. 5, 2016 | N/A | Aloxi® (palonosetron hydrochloride for injection) | 9,173,942 |
Helsinn Healthcare S.A. v. Sagent Pharms., Inc., 16-0681 (D.N.J.) | Feb. 8, 2016 | Hon. Mary L. Cooper | Aloxi® (palonosetron hydrochloride for injection) |
7,947,724
7,947,725
7,960,424
8,598,219
8,729,094
|
Cubist Pharms. LLC v. Crane Pharms. LLC, 16-0072 (D. Del.) | Feb. 10, 2016 | Hon. Gregory M. Sleet | Cubicin® (daptomycin for injection) |
6,468,967
6,852,689
8,058,238
8,129,342
|
Bristol-Myers Squibb Co. v. Cipla USA, Inc., 16-0074 (D. Del.) | Feb. 11, 2016 | Hon. Leonard P. Stark | Reyataz® (atazanavir sulfate capsules) | 6,087,383 |
Pfizer Inc. v. Accord Healthcare, Inc., 16-0079 (D. Del.) | Feb. 11, 2016 | Hon. Sue L. Robinson | Tygacil® (tigecycline injectable IV infusion) |
7,879,828
8,372,995
8,975,242
|
Pfizer Inc. v. Accord Healthcare, Inc., 16-0113 (M.D.N.C.) | Feb. 12, 2016 | Hon. Thomas D. Schroeder | Tygacil® (tigecycline injectable IV infusion) |
7,879,828
8,372,995
8,975,242
|
Purdue Pharma L.P. v. Epic Pharma, LLC, 16-0087 (D. Del.) | Feb. 16, 2016 | Hon. Sue L. Robinson | OxyContin® (oxycodone hydrochloride extended-release tablets) | 9,073,933 |
AstraZeneca Pharms. LP v. Innopharma, Inc., 16-0894 (D.N.J.) | Feb. 16, 2016 | Hon. Renee Marie Bumb | Faslodex® (fulvestrant injection) |
6,774,122
7,456,160
8,329,680
8,466,139
|
Mylan Pharms. Inc. v. Yeda Research * Development Co., Ltd., PGR2016-00010 (PTAB) | Feb. 16, 2016 | N/A | Copaxone® (glatiramer acetate injection) | 9,155,776 |
Boehringer Ingelheim Pharms. Inc. v. Prinston Pharm. Inc., 16-0851 (D.N.J.) | Feb. 17, 2016 | Hon. Peter G. Sheridan | Jentadueto® (linagliptin / metformin hydrochloride tablets) |
8,673,927
8,846,695
|
Boehringer Ingelheim Pharms. Inc. v. Accord Healthcare, Inc., 16-0852 (D.N.J.) | Feb. 17, 2016 | Hon. Peter G. Sheridan | Jentadueto® (linagliptin / metformin hydrochloride tablets) | 9,173,859 |
Par Pharm., Inc. v. Novartis AG, IPR2016-00078 (PTAB) | Oct. 26, 2015 | N/A | Zortress® (everolimus tablets) | 6,455,518 |
Par Pharm., Inc. v. Novartis AG, IPR2016-00084 (PTAB) | Oct. 26, 2015 | N/A | Zortress® (everolimus tablets) | 5,665,772 |
Complex Innovations, LLC v. Amgen Inc., IPR2016-00085 (PTAB) | Oct. 26, 2015 | N/A | Sensipar® (cinacalcet hydrochloride tablets) | 7,829,595 |
Mylan Labs. Ltd. v. Aventis Pharma S.A., IPR2016-00627 (PTAB) | Feb. 17, 2016 | N/A | Jevtana® Kit (cabazitaxel solution for infusion) | 5,847,170 |
Valeant Pharms. Int’l, Inc. v. Actavis LLC, 16-0889 (D.N.J.) | Feb. 18, 2016 | Hon. Stanley R. Chesler | Relistor® (methylnaltrexone bromide injection) |
8,247,425
8,420,663
8,552,025
8,822,490
9,180,125
|
Merck Sharp & Dohme Corp. v. Par Sterile Products, LLC, 16-0948 (D.N.J.) | Feb. 19, 2016 | Hon. Peter G. Sheridan | Noxafil® (posaconazole solution for infusion) | 9,023,790 |
Sandoz Inc. v. Daiichi Sankyo, Inc., 16-0994 (D.N.J.) | Feb. 22, 2016 | Hon. Renee Marie Bumb | Benicar® (olmesartan medoxomil tablets) | 6,878,703 |
Biomarin Pharm. Inc. v. Par Pharm., Inc., 16-1015 (D.N.J.) | Feb. 22, 2016 | Hon. Michael A. Shipp | Kuvan® (sapropterin dihydrochloride packets) |
7,566,714
7,612,073
8,067,416
RE43,797
|
Frontier Therapeutics, LLC v. medac Gesellschaft für klinische Spezialpräparate mbH, IPR2016-00649 (PTAB) | Feb. 22, 2016 | N/A | Rasuvo® (methotrexate solution) | 8,664,231 |
Sandoz Inc. v. Daiichi Sankyo, Inc., 16-0081 (E.D. Va.) | Feb. 22, 2016 | Hon. Arenda L. Wright Allen | Benicar® (olmesartan medoxomil tablets) | 6,878,703 |
Janssen Products, L.P. v. Lupin Ltd., 16-1032 (D.N.J.) | Feb. 23, 2016 | Hon. William H. Walls | Prezista® (darunavir tablets) |
8,518,987
7,126,015
|
Mylan Pharms., Inc. v. Senju Pharm. Co., Ltd., IPR2016-00626 (PTAB) | Feb. 25, 2016 | N/A | Bepreve® (bepotastine besilate ophthalmic solution) | 8,784,789 |
Eli Lilly and Co. v. Biocon Ltd., 16-0469 (S.D. Ind.) | Feb. 26, 2016 | Hon. Tanya Walton Pratt | Alimta® (pemetrexed disodium injection) | 7,772,209 |
Senju Pharm. Co., Ltd. v. Lupin Ltd., 16-1097 (D.N.J.) | Feb. 26, 2016 | Hon. Jerome B. Simandle | Prolensa® (bromfenac ophthalmic solution) | 9,144,609 |
Dow Pharm. Sciences, Inc. v. Actavis Labs. UT, Inc., 16-1105 (D.N.J.) | Feb. 26, 2016 | Hon. Stanley R. Chesler | Onexton® (benzoyl peroxide / clindamycin phosphate topical gel) | 8,288,434 |
Roxane Labs., Inc. v. Vanda Pharms., Inc., 16-0179 (S.D. Ohio) | Feb. 26, 2016 | Hon. Algenon L. Marbley | Fanapt® (iloperidone tablets) |
8,652,776
8,999,638
9,072,742
9,074,254
9,074,255
9,074,256
9,157,121
|
Roxane Labs., Inc. v. Vanda Pharms. Inc., IPR2016-00690 (PTAB) | Feb. 26, 2016 | N/A | Fanapt® (iloperidone tablets) | 9,138,432 |
Delcor Asset Corp. v. Taro Pharm. Industries, Ltd., 16-0117 (D. Del.) | Mar. 1, 2016 | Hon. Gregory M. Sleet | Olux-E® (clobetasol propionate topical aerosol foam) |
6,730,288
7,029,659
|
Duchesnay Inc. v. Apotex Inc., 16-0123 | Mar. 2, 2016 | Hon. Sue L. Robinson | Diclegis® (doxylamine succinate / pyridoxine hydrochloride delayed-release tablets) | 6,340,695 |
Shire Development LLC v. Lupin Ltd., 16-0612 (D. Md.) | Mar. 2, 2016 | Hon. James K. Bredar | Fosrenol® (lanthanum carbonate oral powder) |
5,968,976
7,465,465
8,980,327
9,023,397
|
Alcon Research, Ltd. v. Watson Labs., Inc., 16-0129 (D. Del.) | Mar. 4, 2016 | Hon. Sue L. Robinson | Ilevro® (nepafenac ophthalmic suspension) |
7,947,295
8,921,337
|
Pernix Ireland Pain Ltd. v. Actavis Labs. FL, Inc., 16-0138 (D. Del.) | Mar. 4, 2016 | Hon. Gregory M. Sleet | Zohydro® (hydrocodone bitartrate extended-release capsules) | 9,265,760 |
Pernix Ireland Pain Ltd. v. Alvogen Malta Operations Ltd., 16-0139 (D. Del.) | Mar. 4, 2016 | Hon. Gregory M. Sleet | Zohydro® (hydrocodone bitartrate extended-release capsules) | 9,265,760 |
Takeda Gmbh v. Hetero USA Inc., 16-1280 (D.N.J.) | Mar. 4, 2016 | Hon. Freda L. Wolfson | Daliresp® (roflumilast tablets) | 5,712,298 |
Torrent Pharms. Ltd. v. Daiichi Sankyo, Inc., 16-2988 (N. D. Ill.) | Mar. 9, 2016 | Hon. Rebecca R. Pallmeyer | Benicar® (olmesartan medoxomil tablets) | 6,878,703 |
Cosmo Technologies Ltd. v. Mylan Pharms. Inc., 16-0152 (D. Del.) | Mar. 10, 2016 | Hon. Leonard P. Stark | Uceris® (budesonide tablets) |
7,410,651
8,293,273
8,784,888
RE43,799
|
Senju Pharm. Co., Ltd. v. Innopharma Licensing, Inc., 16-1361 (D.N.J.) | Mar. 10, 2016 | Hon. Jerome B. Simandle | Prolensa® (bromfenac ophthalmic solution) | 9,144,609 |
Ranbaxy Inc. v. Jazz Pharms., Inc., IPR2016-00738 (PTAB) | Mar. 10, 2016 | N/A | Xyrem® (sodium oxybate oral solution) | 9,050,302 |
Purdue Pharma L.P. v. Actavis Labs. FL, Inc., 16-0156 (D. Del.) | Mar. 11, 2016 | Hon. Gregory M. Sleet | Hysingla® ER (hydrocodone bitartrate extended-release tablets) |
9,198,863
9,205,056
|
Cosmo Technologies Ltd. v. Mylan Pharms. Inc., 16-0040 (N.D.W.V.) | Mar. 15, 2016 | Hon. Irene M. Keeley | Uceris® (budesonide tablets) |
7,410,651
8,293,273
8,784,888
RE43,799
|
Mylan Labs. Ltd. v. Aventis Pharma S.A., IPR2016-00712 (PTAB) | Mar. 15, 2016 | N/A | Jevtana® Kit (cabazitaxel solution for infusion) | 8,927,592 |
Eli Lilly and Co. v. Teva Pharms. USA, Inc., 16-0596 (S.D. Ind.) | Mar. 16, 2016 | Hon. Tanya Walton Pratt | Forteo® (teriparatide injection) |
6,770,623
7,144,861
7,550,434
6,977,077
7,163,684
7,351,414
|
Eli Lilly and Co. v. Teva Pharms. USA, Inc., 16-0167 (D. Del.) | Mar. 17, 2016 | Hon. Sue L. Robinson | Forteo® (teriparatide injection) |
6,770,623
7,144,861
7,550,434
6,977,077
7,163,684
7,351,414
|
Fresenius Kabi USA, LLC v. Dr. Reddy’s Labs., Inc., 16-0169 (D. Del.) | Mar. 17, 2016 | Hon. Gregory M. Sleet | Levothyroxine Sodium |
9,006,289
9,168,238
9,168,239
|
Jazz Pharms., Inc. v. Watson Labs., Inc., 16-1505 (D.N.J.) | Mar. 17, 2016 | Hon. Esther Salas | Xyrem® (sodium oxybate oral solution) | 9,050,302 |
Amag Pharms., Inc. v. Sandoz Inc., 16-1508 (D.N.J.) | Mar. 17, 2016 | Hon. Peter G. Sheridan | Feraheme® (ferumoxytol for injection) |
6,599,498
7,553,479
7,871,597
8,501,158
8,591,864
8,926,947
|
BioDelivery Sciences Int’l, Inc. v. Actavis Labs. UT, Inc., 16-0175 (D. Del.) | Mar. 18, 2016 | Hon. Gregory M. Sleet | Bunavail® (buprenorphine / naloxone buccal film) |
7,579,019
8,147,866
8,703,177
|
Senju Pharm. Co., Ltd. v. Watson Labs., Inc., 16-1522 (D.N.J.) | Mar. 18, 2016 | Hon. Jerome B. Simandle | Prolensa® (bromfenac ophthalmic solution) | 9,144,609 |
Fresenius Kabi USA, LLC v. Dr. Reddy’s Labs., Inc., 16-1542 (D.N.J.) | Mar. 18, 2016 | Hon. Kevin McNulty | Levothyroxine Sodium |
9,006,289
9,168,238
9,168,239
|
Indivior Inc. Teva Pharms. USA, Inc., 16-0178 (D. Del.) | Mar. 21, 2016 | Hon. Richard G. Andrews | Suboxone® (buprenorphine hydrochloride / naloxone hydrochloride sublingual film) |
8,475,832
8,017,150
8,603,514
8,900,497
8,906,277
|
Medicis Pharm. Corp. v. Zydus Pharms. (USA) Inc., 16-1565 (D.N.J.) | Mar. 21, 2016 | Hon. Renee Marie Bumb | Vanos® (fluocinonide topical cream) |
6,765,001
7,220,424
7,794,738
8,232,264
|
Salix Pharms., Ltd. v. Actavis Labs. FL, Inc., 16-0188 (D. Del.) | Mar. 23, 2016 | Hon. Gregory M. Sleet | Xifaxan® (rifaximin tablets) |
6,861,053
7,045,620
7,452,857
7,605,240
7,612,199
7,718,608
7,902,206
7,906,542
7,915,275
7,935,799
8,158,644
8,158,781
8,193,196
8,309,569
8,518,949
8,642,573
8,741,904
8,829,017
8,835,452
8,853,231
8,946,252
8,969,398
|
Praxair Distribution, Inc. v. Mallinckrodt Hospital Products IP Ltd., IPR2016-00777 (PTAB) | Mar. 23, 2016 | N/A | Inomax® (nitric oxide) | 8,282,966 |
Praxair Distribution, Inc. v. Mallinckrodt Hospital Products IP Ltd., IPR2016-00778 (PTAB) | Mar. 23, 2016 | N/A | Inomax® (nitric oxide) | 8,431,163 |
Praxair Distribution, Inc. v. Mallinckrodt Hospital Products IP Ltd., IPR2016-00779 (PTAB) | Mar. 23, 2016 | N/A | Inomax® (nitric oxide) | 8,293,284 |
Praxair Distribution, Inc. v. Mallinckrodt Hospital Products IP Ltd., IPR2016-00780 (PTAB) | Mar. 23, 2016 | N/A | Inomax® (nitric oxide) | 8,795,741 |
Praxair Distribution, Inc. v. Mallinckrodt Hospital Products IP Ltd., IPR2016-00781 (PTAB) | Mar. 23, 2016 | N/A | Inomax® (nitric oxide) | 8,846,112 |
Genzyme Corp. v. Sun Pharma Global FZE, 16-1635 (D.N.J.) | Mar. 24, 2016 | Hon. Claire C. Cecchi | Clolar® (clofarabine for injection) | 5,661,136 |
AstraZeneca AB v. Macleods Pharms. Ltd., 16-1682 (D.N.J.) | Mar. 24, 2016 | Hon. Mary L. Cooper | Nexium® (esomeprazole magnesium delayed-release capsules) |
6,369,085
7,411,070
8,466,175
|
Helsinn Healthcare S.A. v. Actavis LLC, 16-1683 (D.N.J.) | Mar. 24, 2016 | Hon. Mary L. Cooper | Aloxi® (palonosetron hydrochloride for injection) |
7,947,724
9,066,980
|
Gilead Sciences, Inc. v. Mylan Pharms. Inc., 16-0192 (D. Del.) | Mar. 25, 2016 | Hon. Richard G. Andrews | Tybost® (cobicistat tablets) | 8,148,374 |
Rhodes Pharms. L.P. v. Actavis, Inc., 16-1668 (D.N.J.) | Mar. 25, 2016 | Hon. William H. Walls | Aptensio XR® (methylphenidate hydrochloride extended-release capsules) |
6,419,960
7,083,808
7,247,318
7,438,930
8,580,310
9,066,869
|
Alcon Research, Ltd. v. Lupin Ltd., 16-0195 (D. Del.) | Mar. 28, 2016 | Hon. Sue L. Robinson | Pazeo® (olopatadine hydrochloride ophthalmic solution) | 8,791,154 |
Boehringer Ingelheim Pharms. Inc. v. Sun Pharm. Industries Ltd., 16-1727 (D.N.J.) | Mar. 29, 2016 | Hon. Peter G. Sheridan |
Tradjento® (linagliptin tablets)
Jentadueto® (linagliptin / metformin hydrochloride tablets)
|
9,173,859 |
Gilead Sciences, Inc. v. Mylan Pharms. Inc., 16-0053 (N.D.W.V.) | Mar. 30, 2016 | Hon. Irene M. Keeley | Tybost® (cobicistat tablets) | 8,148,374 |
Galderma Labs., L.P. v. Amneal Pharms., LLC, 16-0207 (D. Del.) | Mar. 31, 2016 | Hon. Leonard P. Stark | Oracea® (doxycycline capsules) |
7,211,267
7,232,572
8,603,506
9,241,946
7,749,532
8,206,740
8,394,405
8,394,406
8,470,364
8,709,478
|
Merck Sharp & Dohme Corp. v. Roxane Labs., Inc., 16-1804 (D.N.J.) | Mar. 31, 2016 | Hon. Peter G. Sheridan | Noxafil® (posaconazole oral suspension) |
5,661,151
6,958,337
|
United Therapeutics Corp. v. Actavis Labs. FL, Inc., 16-1816 (D.N.J.) | Mar. 31, 2016 | Hon. Peter G. Sheridan | Orenitram® (treprostinil extended-release tablets) |
7,417,070
7,544,713
8,252,839
8,349,892
8,410,169
8,497,393
9,050,311
8,747,897
9,278,910
|
GENERICally Speaking Spring 2016
Related Publications
Fourth Quarter
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Christine May
December 29, 2023
Corcept Therapeutics, Inc. v. Teva Pharms. USA, Inc.
GENERICally Speaking Hatch Waxman Bulletin
December 13, 2023
Acadia Pharms. Inc. v. Aurobindo Pharma Ltd.
GENERICally Speaking Hatch Waxman Bulletin
December 7, 2023
H. Lundbeck A/S v. Lupin Ltd.
GENERICally Speaking Hatch Waxman Bulletin
November 7, 2023
Eisai R&D Mgmt. Co., Ltd. v. Dr Reddy’s Labs., Inc.
GENERICally Speaking Hatch Waxman Bulletin
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.